Physician profile
David L Super
NPI 1083660989
$2,361.17
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,189 · 2020: $76.95 · 2021: $81.63 · 2022: $13.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,461.04 | 2019 | |
| Allergan, INC. | $326.51 | 2019-2020 | |
| Abbvie INC. | $145.45 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.92 | 2019-2021 | |
| Astellas Pharma US INC | $64.08 | 2019 | |
| Merck Sharp & Dohme LLC | $47.59 | 2019 | |
| Duchesnay USA Incorporated | $30.56 | 2019 | |
| Lupin INC. | $28.09 | 2019-2020 | |
| Organon LLC | $26.84 | 2021-2022 | |
| Avion Pharmaceuticals | $22.82 | 2021 | |
| Covidien LP | $22.18 | 2019 | |
| Exeltis, USA INC. | $22.17 | 2019-2020 | |
| Davol INC. | $20.84 | 2019 | |
| Mayne Pharma Commercial LLC | $19.30 | 2021 | |
| Aesculap, INC. | $16.73 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $14.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Super listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.